FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating cyclin D1 and phospho-Akt in mantle cell lymphoma

Clinical Cancer Research

Volumn 16, Issue 12, 2010, Pages 3182-3192

  Liu, Qing ^a   Alinari, Lapo ^a   Chen, Ching Shih ^a   Yan, Fengting ^a   Dalton, James T ^a   Lapalombella, Rosa ^a   Zhang, Xiaoli ^a   Mani, Rajeswaran ^a   Lin, Teresa ^a   Byrd, John C ^a   Baiocchi, Robert A ^a   Muthusamy, Natarajan ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OSUCCC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYCLIN D1; FINGOLIMOD; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN D1; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MICE; MICE, SCID; PROPYLENE GLYCOLS; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SPHINGOSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953694847     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2484     Document Type: Article

References (32)

1. Williams ME, Densmore JJ. Biology and therapy of mantle cell lymphoma. Curr Opin Oncol 2005;17:425-31.
2. Zelenetz AD. Mantle cell lymphoma: an update on management. Ann Oncol 2006;17 Suppl 4:iv12-4.
3. Goy A, Feldman T. Expanding therapeutic options in mantle cell lymphoma. Clin Lymphoma Myeloma 2007;7 Suppl 5:S184-91.
4. Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006;108:1668-76. (Pubitemid 44316136)
5. Bertoni F, Zucca E, Cotter FE. Molecular basis of mantle cell lymphoma. Br J Haematol 2004;124:130-40. (Pubitemid 38122184)
6. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-9.
7. Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005;79:1553-60. (Pubitemid 40847587)
8. Yasui H, Hideshima T, Raje N, et al. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res 2005;65:7478-84. (Pubitemid 41161283)
9. Liu Q, Zhao X, Frissora F, et al. FTY720 demonstrates promising pre-clinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008;111:275-84.
10. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000;13:193-207.
11. Amin HM, McDonnell TJ, Medeiros LJ, et al. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 2003;127:424-31.
12. Marchetti P, Castedo M, Susin SA, et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 1996;184:1155-60.
13. Tanaka T, Kitamura F, Nagasaka Y, et al. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor â chain monoclonal antibody in mice. J Exp Med 1993;178:1103-7. (Pubitemid 23260450)
14. Hung JH, Lu YS, Wang YC, et al. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C δ signaling. Cancer Res 2008;68:1204-12.
15. Liu HB, Cui NQ, Wang Q, et al. Sphingosine-1-phosphate and its analogue FTY720 diminish acute pulmonary injury in rats with acute necrotizing pancreatitis. Pancreas 2008;36:e10-5.
16. Tan S, Sagara Y, Liu Y, et al. The regulation of reactive oxygen species production during programmed cell death. J Cell Biol 1998;141:1423-32.
17. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008;118:3051-64.
18. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-74.
19. Suzuki S, Enosawa S, Kakefuda T, et al. Long-term graft acceptance in allografted rats and dogs by treatment with a novel immunosuppressant, FTY720. Transplant Proc 1996;28:1375-6. (Pubitemid 26195927)
20. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996;61:200-5. (Pubitemid 26046580)
21. Degan M, Doliana R, Gloghini A, et al. A novel bcl-1/JH breakpoint from a patient affected by mantle cell lymphoma extends the major translocation cluster. J Pathol 2002;197:256-63. (Pubitemid 34567614)
22. Pott C, Tiemann M, Linke B, et al. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia 1998;12:1630-7. (Pubitemid 28470450)
23. Georgakis GV, Li Y, Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006;135:68-71. (Pubitemid 44337664)
24. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphom: a clinicopathologic study based on gene expression profiling. Blood 2005;106:4315-21. (Pubitemid 41775942)
25. Klier M, Anastasov N, Hermann A, et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effect on cell survival and reveals regulatory circuit with cyclin D2. Leukemia 2008;22:2097-105.
26. Nagahara Y, Matsuoka Y, Saito K, et al. Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720. Jpn J Cancer Res 2001;92:680-7. (Pubitemid 32633472)
27. Toker A, Newton AC. Cellular signaling: pivoting around PDK-1. Cell 2000;103:185-8.
28. Toker A, Newton AC. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 2000;275:8271-4. (Pubitemid 30180163)
29. Tsuruta F, Masuyama N, Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J Biol Chem 2002;277:14040-7. (Pubitemid 34968013)
30. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003;278:33714-23. (Pubitemid 37553204)
31. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 1998;95:4997-5002. (Pubitemid 28208539)
32. Lentzsch S, Chatterjee M, Gries M, et al. PI3-K/AKT/FKHR andMAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004;18:1883-90. (Pubitemid 39530020)